PHASE 1 STUDY OF ARV-393, A PROTAC BCL6 DEGRADER, AS MONOTHERAPY IN PATIENTS WITH ADVANCED NON-HODGKIN LYMPHOMA (NHL) OR COMBINED WITH GLOFITAMAB IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
EHA Library, Sarit Assouline,
4210286
TRANSFERRIN AS AN EARLY OUTCOME PREDICTOR IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA RECEIVING POLATUZUMAB VEDOTIN IN COMBINATION WITH RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, AND PREDNISONE
EHA Library, Ziyang Shi,
4210294
RED CELL DISTRIBUTION WIDTH, SERUM ALBUMIN, AND LACTATE DEHYDROGENASE AS A COMPOSITE PROGNOSTIC SCORE (RAL) IN DIFFUSE LARGE B-CELL LYMPHOMA: A MULTICENTER RETROSPECTIVE COHORT STUDY
EHA Library, Dragana Grohovac,
4210309
COMPARISON OF ORELABRUTINIB, RITUXIMAB, AND METHOTREXATE (OR-MTX) VERSUS RITUXIMAB AND METHOTREXATE (R-MTX) IN FIRST-LINE TREATMENT OF PRIMARY CNS LYMPHOMA: A RETROSPECTIVE ANALYSIS
EHA Library, Fang shu Guan,
4210313
A PROSPECTIVE, SINGLE-ARM, PHASE Ⅱ TRIAL OF THIOTEPA, PIRTOBRUTINIB AND SINTILIMAB (TPP) IN PATIENTS WITH UNFIT OR RELAPSED/REFRACTORY PRIMARY OR SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA
EHA Library, Li Cong,
4210320
POOR PERFORMANCE STATUS MAY PRECLUDE THE USE OF RITUXIMAB, METHOTREXATE, PROCARBAZINE, AND VINCRISTINE IN INDUCTION THERAPY OF PRIMARY CNS DLBCL: A SINGLE-CENTER EXPERIENCE
EHA Library, Vojin Vukovic,
4210361